« Previous AbstractPacking material formulation for odorous emission biofiltration    Next Abstract"Systemic Induction of NO-, Redox-, and cGMP Signaling in the Pumpkin Extrafascicular Phloem upon Local Leaf Wounding" »

Chest

Title:		Real-Time Breath Analysis Reveals Specific Metabolic Signatures of COPD Exacerbations
Author(s):		Gaugg MT; Nussbaumer-Ochsner Y; Bregy L; Engler A; Stebler N; Gaisl T; Bruderer T; Nowak N; Sinues P; Zenobi R; Kohler M;
Address:		"Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland. Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland. Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; Division of Respiratory Medicine, Childhood Research Center, University Children's Hospital Zurich, Zurich, Switzerland. Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; University Children's Hospital Basel, University of Basel, Basel, Switzerland. Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland; Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland. Electronic address: Malcolm.Kohler@usz.ch"
Journal Title:		Chest
Year:		2019
Volume:		20190124
Issue:		2
Page Number:		269 - 276
DOI:		10.1016/j.chest.2018.12.023
ISSN/ISBN:		1931-3543 (Electronic) 0012-3692 (Linking)
Abstract:		"BACKGROUND: Exacerbations of COPD are defined by acute worsening of respiratory symptoms leading to a change in therapy. Identifying altered metabolic processes in patients at risk for future exacerbations is desirable for treatment optimization, the development of new therapeutic strategies, and perhaps diagnostic value. We aimed to identify affected pathways using the profiles of volatile organic compounds in exhaled breath from patients with COPD with and without frequent exacerbations (>/= 2 exacerbations within the past 12 months). METHODS: In this matched cohort study, exhaled breath profiles from patients with COPD and frequent exacerbations ('frequent exacerbators') and without frequent exacerbations ('nonfrequent exacerbators') were analyzed during an exacerbation-free interval using real-time secondary electrospray ionization high-resolution mass spectrometry. We analyzed exhaled breath from 26 frequent exacerbators and 26 nonfrequent exacerbators that were matched in terms of age, sex, and smoking history. To obtain new pathophysiological insights, we investigated significantly altered metabolites, which can be assigned to specific pathways. Metabolites were identified by using a Wilcoxon rank-sum test. RESULTS: Metabolite levels from the omega-oxidation pathway, namely omega-hydroxy, omega-oxo, and dicarboxylic acids, were consistently decreased in frequent exacerbators. Additionally, several new nitro-aromatic metabolites, which were significantly increased in frequent exacerbators, were identified. CONCLUSIONS: Real-time breath analysis by secondary electrospray high-resolution mass spectrometry allows molecular profiling of exhaled breath, providing insights about ongoing biochemical processes in patients with COPD at risk for exacerbations. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02186639; URL: www.clinicaltrials.gov"
Keywords:		"Adult Aged Aged, 80 and over Biomarkers/metabolism Breath Tests Cohort Studies Disease Progression Exhalation Female Humans Male Middle Aged Pulmonary Disease, Chronic Obstructive/*complications/*metabolism Spectrometry, Mass, Electrospray Ionization Copd;"
Notes:		"MedlineGaugg, Martin Thomas Nussbaumer-Ochsner, Yvonne Bregy, Lukas Engler, Anna Stebler, Nina Gaisl, Thomas Bruderer, Tobias Nowak, Nora Sinues, Pablo Zenobi, Renato Kohler, Malcolm eng Research Support, Non-U.S. Gov't 2019/01/28 Chest. 2019 Aug; 156(2):269-276. doi: 10.1016/j.chest.2018.12.023. Epub 2019 Jan 24"